The publications below are the bibliography of Markus Seeliger and his lab at Stony Brook University. Works from his PhD with Laura Itzhaki and postdoc research with John Kuriyan are also included; including publications which are hard to find on PubMed.
2024
Leyte-Vidal A., DeFilippis R., Outhwaite I.R., Kawn I, Lee J.Y., Leavitt C., Miller K.B., Rea D., Rangwala A.M., Lou K., Patel S., Alvarez A., Shokat K.M., Bahar I., Seeliger M.A., Shah N.P. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia. 2024. https://doi.org/10.1038/s41375-024-02353-0
Lee S, Wang D, Seeliger MA, Tiwary P. Calculating Protein-Ligand Residence Times through State Predictive Information Bottleneck Based Enhanced Sampling. J Chem Theory Comput. 2024 Jul 11. PMID: 38991145. https://doi.org/10.1021/acs.jctc.4c00503
Chouhan S, Sridaran D, Weimholt C, Luo J, Li T, Hodgson MC, Santos LN, Le Sommer S, Fang B, Koomen JM, Seeliger M, Qu CK, Yart A, Kontaridis MI, Mahajan K, Mahajan NP. SHP2 as a primordial epigenetic enzyme expunges histone H3 pTyr-54 to amend androgen receptor homeostasis. Nat Commun. 2024 Jul 4;15(1):5629. PMID: 38965223; PMCID: PMC11224269. https://doi.org/10.1038%2Fs41467-024-49978-4
Ghebrehiwet B, Zaniewski M, Fernandez A, DiGiovanni M, Reyes TN, Ji P, Savitt AG, Williams JL, Seeliger MA, Peerschke EIB. The C1q and gC1qR axis as a novel checkpoint inhibitor in cancer. Front Immunol. 2024 Apr 22;15:1351656. doi: 10.3389/fimmu.2024.1351656. PMID: 38711524; PMCID: PMC11070495.
Berezovsky IN, Seeliger MA. Editorial overview: Molecular determinants, mechanisms, and state-of-the-art approaches in allostery. Curr Opin Struct Biol. 2024 Jun;86:102810. doi: 10.1016/j.sbi.2024.102810. Epub 2024 Apr 4. PMID: 38579516.
Gebauer E, Seeliger MA. All the mutations that are fit to die. Cell Chem Biol. 2024 Feb 15. Vol 31; issue 2:192-194. doi: https://doi.org/10.1016/j.chembiol.2024.01.005
Lee JY, Gebauer E, Seeliger MA, Bahar I. Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments. Curr Opin Struct Biol. 2024 Jan 10;84:102770. doi: https://doi.org/10.1016/j.sbi.2023.102770. PMID: 38211377
2023
Outhwaite IR, Singh S, Berger BT, Knapp S, Chodera JD, Seeliger MA. Death by a thousand cuts through kinase inhibitor combinations that maximize selectivity and enable rational multitargeting. Elife. 2023 Dec 4;12:e86189. doi: https://doi.org/10.7554/eLife.86189. PMID: 38047771.
Outhwaite IR, Seeliger MA. Probing conformational dynamics to understand kinase inhibition. Elife (insight article). 2023 Oct 18;12:e92753. doi: https://doi.org/10.7554/eLife.92753. PMID: 37850630; PMCID: PMC10584368.
Ayaz P*, Lyczek A*, Paung Y, Mingione VR, Iacob RE, de Waal PW, Engen JR, Seeliger MA, Shan Y, Shaw DE. Structural mechanism of a drug-binding process involving a large conformational change of the protein target. Nat Commun. 2023 Apr 5;14(1):1885. doi: https://doi.org/10.1038/s41467-023-36956-5. PMID: 37019905; PMCID: PMC10076256. (*co-first authors)
Kan Y, Paung Y, Seeliger MA, Miller WT. Domain Architecture of the Nonreceptor Tyrosine Kinase Ack1. Cells. 2023 Mar 15;12(6):900. doi: https://doi.org/10.3390/cells12060900. PMID: 36980241; PMCID: PMC10047419.
Kan Y, Paung Y, Kim Y, Seeliger MA, Miller WT. Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. Biochemistry. 2023 Mar 21;62(6):1124-1137. doi: https://doi.org/10.1021/acs.biochem.2c00685. Epub 2023 Feb 28. PMID: 36854171; PMCID: PMC10052838.
Mingione VR*, Paung Y*, (*co-first author)
2022
Lou K, Wassarman DR, Yang T, Paung Y, Zhang Z, O’Loughlin TA, Moore MK, Egan RK, Greninger P, Benes CH, Seeliger MA, Taunton J, Gilbert LA, Shokat KM. IFITM proteins assist cellular uptake of diverse linked chemotypes. Science. 2022 Dec 9;378(6624):1097-1104. Epub 2022 Dec 8.PMID: 36480603. DOI: https://doi.org/10.1126/science.abl5829
Sridaran D, Chouhan S, Mahajan K, Renganathan A, Weimholt C, Bhagwat S, Reimers M, Kim EH, Thakur MK, Saeed MA, Pachynski RK, Seeliger MA, Miller WT, Feng FY, Mahajan NP. Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. Nat Commun. 2022;13, 6929. DOI: https://doi.org/10.1038/s41467-022-34724-5
Peterson AA*, Rangwala AM*, Thakur MK, Ward PS, Hung C, Outhwaite IR, Chan AI, Usanov DL, Mootha VK, Seeliger MA, Liu DR. Discovery and molecular basis of subtype-selective cyclophilin inhibitors. Nat Chem Biol. 2022 Nov;18(11):1184-1195. https://pubmed.ncbi.nlm.nih.gov/36163383/ (*co-first authors)
Shekhar M, Smith Z, Seeliger MA*, Tiwary P*. Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases. Angew Chem Int Ed Engl. 2022:e202200983. https://www.ncbi.nlm.nih.gov/pubmed/35486370. (* co-corresponding author).
Weinheimer AS, Paung Y, Rageul J, Khan A, Lo N, Ho B, Tong M, Alphonse S, Seeliger MA, Kim H. Extended DNA-binding interfaces beyond the canonical SAP domain contribute to the function of replication stress regulator SDE2 at DNA replication forks. J Biol Chem. 2022 Aug;298(8):102268. doi: 10.1016/j.jbc.2022.102268. https://pubmed.ncbi.nlm.nih.gov/35850305/ Epub 2022 Jul 16. PMID: 35850305; PMCID: PMC9399289.
Rangwala AM*, Mingione VR*, Georghiou G, Seeliger MA. Kinases on Double Duty: A Review of UniProtKB Annotated Bifunctionality within the Kinome. Biomolecules. 2022;12(5). https://www.ncbi.nlm.nih.gov/pubmed/35625613. (*co-first author)
Mingione VR, Foda ZH, Paung Y, Philipose H, Rangwala AM, Shan Y*, Seeliger MA*. Validation of an Allosteric Binding Site of Src Kinase Identified by Unbiased Ligand Binding Simulations. J Mol Biol. 2022:167628. https://www.ncbi.nlm.nih.gov/pubmed/35595169. (* co-corresponding author)
Aziz M. Rangwala, Benedict-Tilman Berger, Matthew B. Robers, Stefan Knapp & Markus A. Seeliger (2022) Resistance to kinase inhibition through shortened target engagement. Molecular & Cellular Oncology. DOI: 10.1080/23723556.2022.2029999
2021
Lyczek A*, Berger B*, Rangwala AM*, Paung Y, Tom J, Philipose H, Guod J, Albanese SK, Robers MB, Knapp S, Chodera JD, Seeliger MA. Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance . PNAS. 2021;118(46). https://www.pnas.org/content/118/46/e2111451118. (*co-first authors)
2020
Grey MJ, Cloots E, Simpson MS, LeDuc N, Serebrenik YV, De Luca H, De Sutter D, Luong P, Thiagarajah JR, Paton AW, Paton JC, Seeliger MA, Eyckerman S, Janssens S, Lencer WI. IRE1beta negatively regulates IRE1alpha signaling in response to endoplasmic reticulum stress. J Cell Biol. 2020;219(2). https://www.ncbi.nlm.nih.gov/pubmed/31985747.
Fang L, Vilas-Boas J, Chakraborty S, Potter ZE, Register AC, Seeliger MA, Maly DJ. How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture. ACS Chem Biol. 2020;15(7):2005-16. https://www.ncbi.nlm.nih.gov/pubmed/32479050.
2019
Wang J, Chan B, Tong M, Paung Y, Jo U, Martin D, Seeliger M, Haley J, Kim H. Prolyl isomerization of FAAP20 catalyzed by PIN1 regulates the Fanconi anemia pathway. PLoS Genet. 2019;15(2):e1007983. https://www.ncbi.nlm.nih.gov/pubmed/30789902.
Maianti JP, Tan GA, Vetere A, Welsh AJ, Wagner BK, Seeliger MA*, Liu DR*. Substrate-selective inhibitors that reprogram the activity of insulin-degrading enzyme. Nat Chem Biol. 2019;15(6):565-74. https://www.ncbi.nlm.nih.gov/pubmed/31086331. (*co-corresponding author)
Hanson SM, Georghiou G, Thakur MK, Miller WT, Rest JS, Chodera JD*, Seeliger MA*. What Makes a Kinase Promiscuous for Inhibitors? Cell Chem Biol. 2019;26(3):390-9 e5. https://www.ncbi.nlm.nih.gov/pubmed/30612951. (*co-corresponding author). Recommended in F1000.com. Commentary in Science Translation Medicine.
2018
Seeliger MA. More Diversity Yields a Clearer Picture into the Architecture of the Protein Kinase Domain. Cell Syst. 2018;7(4):356-7. https://www.ncbi.nlm.nih.gov/pubmed/30359621.
Paung Y, Seeliger MA. KA1 Domains: Unity in Mechanistic Diversity. Structure. 2018;26(8):1045-7. https://www.ncbi.nlm.nih.gov/pubmed/30089246.
2017
Tong M, Pelton JG, Gill ML, Zhang W, Picart F, Seeliger MA. Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites. Nat Commun. 2017;8(1):2160. https://www.ncbi.nlm.nih.gov/pubmed/29255153
Philip F, Ha EE, Seeliger MA, Frohman MA. Measuring Phospholipase D Enzymatic Activity Through Biochemical and Imaging Methods. Methods in enzymology. 2017;583:309-25. https://www.ncbi.nlm.nih.gov/pubmed/28063496
Kukenshoner T, Schmit NE, Bouda E, Sha F, Pojer F, Koide A, Seeliger M, Koide S, Hantschel O. Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies. J Mol Biol. 2017;429(9):1364-80. https://www.ncbi.nlm.nih.gov/pubmed/28347651.
Chu WT, Nesbitt NM, Gnatenko DV, Li Z, Zhang B, Seeliger MA, Browne S, Mantle TJ, Bahou WF, Wang J. Enzymatic Activity and Thermodynamic Stability of Biliverdin IXbeta Reductase Are Maintained by an Active Site Serine. Chemistry. 2017;23(8):1891-900. https://www.ncbi.nlm.nih.gov/pubmed/27897348
Alford VM, Kamath A, Ren X, Kumar K, Gan Q, Awwa M, Tong M, Seeliger MA, Cao J, Ojima I, Sampson NS. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS Chem Biol. 2017;12(11):2788-803. https://www.ncbi.nlm.nih.gov/pubmed/28945333
Albanese SK, Parton D, Hanson SM, Rodríguez-Laureano L, Işık M, Behr JM, Gradia S, Jeans C, Levinson NM, Seeliger MA, Chodera J. An open library of human kinase domain constructs for automated bacterial expression. bioRxiv. 2017:038711
2016
Lebedev I, Nemajerova A, Foda ZH, Kornaj M, Tong M, Moll UM*, Seeliger MA*. A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems. J Mol Biol. 2016;428(20):4154-67. https://www.ncbi.nlm.nih.gov/pubmed/27515399 (* co-corresponding author)
Kwarcinski FE, Brandvold KR, Phadke S, Beleh OM, Johnson TK, Meagher JL, Seeliger MA, Stuckey JA, Soellner MB. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity. ACS Chem Biol. 2016;11(5):1296-304. https://www.ncbi.nlm.nih.gov/pubmed/26895387
Huculeci R, Cilia E, Lyczek A, Buts L, Houben K, Seeliger MA, van Nuland N, Lenaerts T. Dynamically Coupled Residues within the SH2 Domain of FYN Are Key to Unlocking Its Activity. Structure. 2016;24(11):1947-59. https://www.ncbi.nlm.nih.gov/pubmed/27692963
Feldman HC, Tong M, Wang L, Meza-Acevedo R, Gobillot TA, Lebedev I, Gliedt MJ, Hari SB, Mitra AK, Backes BJ, Papa FR, Seeliger MA*, Maly DJ*. Structural and Functional Analysis of the Allosteric Inhibition of IRE1alpha with ATP-Competitive Ligands. ACS Chem Biol. 2016;11(8):2195-205. https://www.ncbi.nlm.nih.gov/pubmed/27227314 (* co-corresponding author)
Aleem S, Georghiou G, Kleiner RE, Guja K, Craddock BP, Lyczek A, Chan AI, Garcia-Diaz M, Miller WT, Liu DR*, Seeliger MA*. Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles. Cell Chem Biol. 2016;23(9):1103-12. https://www.ncbi.nlm.nih.gov/pubmed/27593110 (* co-corresponding author)
2015
Tong M, Seeliger MA. Targeting conformational plasticity of protein kinases. ACS Chem Biol. 2015;10(1):190-200. https://www.ncbi.nlm.nih.gov/pubmed/25486330
Sawicka KM, Seeliger M, Musaev T, Macri LK, Clark RA. Fibronectin Interaction and Enhancement of Growth Factors: Importance for Wound Healing. Adv Wound Care (New Rochelle). 2015;4(8):469-78. https://www.ncbi.nlm.nih.gov/pubmed/26244103
Foda ZH, Shan Y, Kim ET, Shaw DE, Seeliger MA. A dynamically coupled allosteric network underlies binding cooperativity in Src kinase. Nat Commun. 2015;6:5939.
2014
Maianti JP, McFedries A, Foda ZH, Kleiner RE, Du XQ, Leissring MA, Tang WJ, Charron MJ, Seeliger MA, Saghatelian A, Liu DR. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511(7507):94-8. https://www.ncbi.nlm.nih.gov/pubmed/24847884 (Recommended in F1000.com)
Foda ZH, Seeliger MA. Kinase inhibitors: an allosteric add-on. Nat Chem Biol. 2014;10(10):796-7. https://www.ncbi.nlm.nih.gov/pubmed/25195010
Etheridge SL, Cosgrove ME, Sangkhae V, Corbo LM, Roh ME, Seeliger MA, Chan EL, Hitchcock IS. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood. 2014;123(7):1059-68. https://www.ncbi.nlm.nih.gov/pubmed/24381227 (Recommended in F1000.com)
2013 and prior
Seeliger MA, Moll UM. p73 – constitutively open for business. Cell Death Differ. 2013;20(8):972-3. https://www.ncbi.nlm.nih.gov/pubmed/23832148
Schultheiss KP, Craddock BP, Tong M, Seeliger M, Miller WT. Metazoan-like signaling in a unicellular receptor tyrosine kinase. BMC biochemistry. 2013;14:4. https://www.ncbi.nlm.nih.gov/pubmed/23398683
Hari SB, Perera BG, Ranjitkar P, Seeliger MA, Maly DJ. Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. ACS Chem Biol. 2013;8(12):2734-43. https://www.ncbi.nlm.nih.gov/pubmed/24106839
Wang L, Perera BG, Hari SB, Bhhatarai B, Backes BJ, Seeliger MA, Schurer SC, Oakes SA, Papa FR, Maly DJ. Divergent allosteric control of the IRE1alpha endoribonuclease using kinase inhibitors. Nat Chem Biol. 2012;8(12):982-9. https://www.ncbi.nlm.nih.gov/pubmed/23086298
Montpetit B, Seeliger MA, Weis K. Analysis of DEAD-box proteins in mRNA export. Methods in enzymology. 2012;511:239-54. https://www.ncbi.nlm.nih.gov/pubmed/22713323.
Georghiou G, Kleiner RE, Pulkoski-Gross M, Liu DR*, Seeliger MA*. Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. Nat Chem Biol. 2012;8(4):366-74. https://www.ncbi.nlm.nih.gov/pubmed/22344177 (* co-corresponding author)
Shan Y, Kim ET, Eastwood MP, Dror RO, Seeliger MA, Shaw DE. How does a drug molecule find its target binding site? J Am Chem Soc. 2011;133(24):9181-3. https://www.ncbi.nlm.nih.gov/pubmed/21545110 (Recommended in F1000.com)
Montpetit B, Thomsen ND, Helmke KJ, Seeliger MA, Berger JM, Weis K. A conserved mechanism of DEAD-box ATPase activation by nucleoporins and InsP6 in mRNA export. Nature. 2011;472(7342):238-42. https://www.ncbi.nlm.nih.gov/pubmed/21441902 (Recommended in F1000.com)
Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell. 2011;42(1):9-22. https://www.ncbi.nlm.nih.gov/pubmed/21474065
Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley PW, Adamia S, Wu C, Gray N, Griffin JD. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood. 2010;115(21):4206-16. https://www.ncbi.nlm.nih.gov/pubmed/20299508
Shan Y, Seeliger MA, Eastwood MP, Frank F, Xu H, Jensen MO, Dror RO, Kuriyan J, Shaw DE. A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci U S A. 2009;106(1):139-44. https://www.ncbi.nlm.nih.gov/pubmed/19109437 (Recommended in F1000.com)
Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 2009;69(6):2384-92. https://www.ncbi.nlm.nih.gov/pubmed/19276351 (Recommended in F1000.com)
Seeliger MA, Kuriyan J. A MAPK scaffold lends a helping hand. Cell. 2009;136(6):994-6. https://www.ncbi.nlm.nih.gov/pubmed/19303841.
Muratore KE, Seeliger MA, Wang Z, Fomina D, Neiswinger J, Havranek JJ, Baker D, Kuriyan J, Cole PA. Comparative analysis of mutant tyrosine kinase chemical rescue. Biochemistry-Us. 2009;48(15):3378-86. https://www.ncbi.nlm.nih.gov/pubmed/19260709
Choi Y, Seeliger MA, Panjarian SB, Kim H, Deng X, Sim T, Couch B, Koleske AJ, Smithgall TE, Gray NS. N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor. J Biol Chem. 2009;284(42):29005-14. https://www.ncbi.nlm.nih.gov/pubmed/19679652
Statsuk AV, Maly DJ, Seeliger MA, Fabian MA, Biggs WH, 3rd, Lockhart DJ, Zarrinkar PP, Kuriyan J, Shokat KM. Tuning a three-component reaction for trapping kinase substrate complexes. J Am Chem Soc. 2008;130(51):17568-74. https://www.ncbi.nlm.nih.gov/pubmed/19053485 (Recommended in F1000.com)
Levinson NM, Seeliger MA, Cole PA, Kuriyan J. Structural basis for the recognition of c-Src by its inactivator Csk. Cell. 2008;134(1):124-34. https://www.ncbi.nlm.nih.gov/pubmed/18614016 (Recommended in F1000.com)
Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15(10):1109-18. https://www.ncbi.nlm.nih.gov/pubmed/18794843 (Recommended in F1000.com)
Seeliger MA, Nagar B, Frank F, Cao X, Henderson MN, Kuriyan J. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty. Structure. 2007;15(3):299-311. https://www.ncbi.nlm.nih.gov/pubmed/17355866.
Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, 3rd, Treiber DK, Patel HK, Zarrinkar PP, Lockhart DJ, Sawyers CL, Kuriyan J. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 2006;66(2):1007-14. https://www.ncbi.nlm.nih.gov/pubmed/16424036
Yao ZP, Zhou M, Kelly SE, Seeliger MA, Robinson CV, Itzhaki LS. Activation of ubiquitin ligase SCF(Skp2) by Cks1: insights from hydrogen exchange mass spectrometry. J Mol Biol. 2006;363(3):673-86. https://www.ncbi.nlm.nih.gov/pubmed/16979657.
Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, Kuriyan J. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell. 2006;21(6):787-98. https://www.ncbi.nlm.nih.gov/pubmed/16543148.
Bader R, Seeliger MA, Kelly SE, Ilag LL, Meersman F, Limones A, Luisi BF, Dobson CM, Itzhaki LS. Folding and fibril formation of the cell cycle protein Cks1. J Biol Chem. 2006;281(27):18816-24. https://www.ncbi.nlm.nih.gov/pubmed/16675442
Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, Falick AM, Kuriyan J. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 2005;14(12):3135-9. https://www.ncbi.nlm.nih.gov/pubmed/16260764
Seeliger MA, Spichty M, Kelly SE, Bycroft M, Freund SMV, Karplus M, Itzhaki LS. Role of conformational heterogeneity in domain swapping and adapter function of the Cks proteins. J Biol Chem. 2005;280(34):30448-59. http://www.jbc.org/content/280/34/30448.full.pdf.
Mapelli M, Massimiliano L, Crovace C, Seeliger MA, Tsai LH, Meijer L, Musacchio A. Mechanism of CDK5/p25 binding by CDK inhibitors. J Med Chem. 2005;48(3):671-9. https://www.ncbi.nlm.nih.gov/pubmed/15689152
Seeliger MA, Breward SE, Itzhaki LS. Weak cooperativity in the core causes a switch in folding mechanism between two proteins of the cks family. J Mol Biol. 2003;325(1):189-99. https://www.ncbi.nlm.nih.gov/pubmed/12473461.
Seeliger MA, Breward SE, Friedler A, Schon O, Itzhaki LS. Cooperative organization in a macromolecular complex. Nat Struct Biol. 2003;10(9):718-24. https://www.ncbi.nlm.nih.gov/pubmed/12897769
Sitry D, Seeliger MA, Ko TK, Ganoth D, Breward SE, Itzhaki LS, Pagano M, Hershko A. Three different binding sites of Cks1 are required for p27-ubiquitin ligation. J Biol Chem. 2002;277(44):42233-40. https://www.ncbi.nlm.nih.gov/pubmed/12140288
Seeliger MA, Schymkowitz JW, Rousseau F, Wilkinson HR, Itzhaki LS. Folding and association of the human cell cycle regulatory proteins ckshs1 and ckshs2. Biochemistry-Us. 2002;41(4):1202-10. https://www.ncbi.nlm.nih.gov/pubmed/11802719